Analysts Have Made A Financial Statement On Optomed Oyj's (HEL:OPTOMED) First-Quarter Report

It's been a good week for Optomed Oyj (HEL:OPTOMED) shareholders, because the company has just released its latest quarterly results, and the shares gained 6.3% to €4.06. The results don't look great, especially considering that statutory losses grew 14% to€0.08 per share. Revenues of €4,021,000 did beat expectations by 8.7%, but it looks like a bit of a cold comfort. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

We've discovered 2 warning signs about Optomed Oyj. View them for free.

Taking into account the latest results, the consensus forecast from Optomed Oyj's three analysts is for revenues of €18.2m in 2025. This reflects a solid 16% improvement in revenue compared to the last 12 months. Losses are expected to be contained, narrowing 14% from last year to €0.26. Before this earnings announcement, the analysts had been modelling revenues of €17.9m and losses of €0.14 per share in 2025. So it's pretty clear the analysts have mixed opinions on Optomed Oyj even after this update; although they reconfirmed their revenue numbers, it came at the cost of a regrettable increase in per-share losses.

View our latest analysis for Optomed Oyj

As a result, there was no major change to the consensus price target of €5.37, with the analysts implicitly confirming that the business looks to be performing in line with expectations, despite higher forecast losses. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Optomed Oyj, with the most bullish analyst valuing it at €5.50 and the most bearish at €5.20 per share. Even so, with a relatively close grouping of estimates, it looks like the analysts are quite confident in their valuations, suggesting Optomed Oyj is an easy business to forecast or the the analysts are all using similar assumptions.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Optomed Oyj's rate of growth is expected to accelerate meaningfully, with the forecast 22% annualised revenue growth to the end of 2025 noticeably faster than its historical growth of 1.6% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 14% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Optomed Oyj to grow faster than the wider industry.

The Bottom Line

The most important thing to note is the forecast of increased losses next year, suggesting all may not be well at Optomed Oyj. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at €5.37, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Optomed Oyj. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Optomed Oyj analysts - going out to 2027, and you can see them free on our platform here.

However, before you get too enthused, we've discovered 2 warning signs for Optomed Oyj that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.